This inhibition promotes the secretion of immune-modulatory factors CXCL10, CXCL11, EBI3, and FLT3LG by tumor cells, thereby alleviating immunosuppression and enhancing CD8+ T cell recruitment into the tumor microenvironment and boosting antitumor immunity. This evidence concerns the gene CXCL11 and neoplasm.